GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

View GlaxoSmithKline's Q3 Earnings Report

FiercePharma says: Emerging markets are paying off for GlaxoSmithKline, but it's pandemic flu that's really accelerating sales. Third-quarter profits jumped by 30 percent to £1.34 billion ($2.18 billion), partly on currency effects, while sales grew 15 percent to £6.76 billion ($11.05 billion). Read more...


  • Return to sales growth with Q3 turnover +3% CER; +15% sterling
  • Continued improvement expected in Q4
  • Portfolio diversification and investment in key areas drives return to sales growth: Emerging Markets (+25%); Japan (+19%) and Consumer Healthcare (+8%)
  • Further growth expected in Q4 2009 including significant sales of influenza products
  • US sales -12% primarily due to continued adverse impact of generic competition

Check out GSK's current estimates from CNN Money

GSK's Website:

GlaxoSmithKline Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.